Blood, Bone Marrow Aspirate, or Formalin Fixed Paraffin Embedded Clot block (or 10 unstained 4-8 micron thick sections on non-plus slides and an H&E slide of the clot)

Specimen requires 20% or greater tumor cell content.

3 mL blood -OR- bone marrow in a pink EDTA top tube. Requires dedicated tube for molecular only.

Specimen requires 20% or greater tumor cell content. Submit formalin fixed paraffin embedded tissue and ten unstained 4 micron-thick sections on non-plus slides.

Specimens fixed in B5 fixative or decalcified will not be accepted. Tumor specimens containing less than 20% tumor cells may be unacceptable.

Twice Weekly

10-14 days upon receipt in laboratory

The Acute Myelogenous Leukemia Profiling test is a massively parallel next generation DNA sequencing-based assay that targets cancer-related genes.

Genes Assessed: ANKRD26, ASXL1, BCOR*, BRAF, CBL, CEBPA*, DDX41, DNMT3A, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, KMT2A* (MLL), NF1*, NPM1, NRAS, PHF6*, PPM1D, PTEN*, PTPN11, RUNX1*, SETBP1, SF3B1, SRSF2, STAG2*, TET2*, TP53, U2AF1, UBA1, WT1 and ZRSR2*.

Sequencing is limited to targeted gene regions unless marked with an asterisk indicating full coding sequence coverage.

Massively parallel Next Generation DNA sequencing by synthesis